Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials

MLA

Hong-Xing Pan, et al. “Immunogenicity and Safety of a Severe Acute Respiratory Syndrome Coronavirus 2 Inactivated Vaccine in Healthy Adults: Randomized, Double-Blind, and Placebo-Controlled Phase 1 and Phase 2 Clinical Trials.” Chinese Medical Journal, vol. 134, no. 11, June 2021, pp. 1289–98. EBSCOhost, https://doi.org/10.1097/CM9.0000000000001573.

APA

Hong-Xing Pan, Jian-Kai Liu, Bao-Ying Huang, Gui-Fan Li, Xian-Yun Chang, Ya-Fei Liu, Wen-Ling Wang, Kai Chu, Jia-Lei Hu, Jing-Xin Li, Dan-Dan Zhu, Jing-Liang Wu, Xiao-Yu Xu, Li Zhang, Meng Wang, Wen-Jie Tan, Wei-Jin Huang, Feng-Cai Zhu, & Jing Ni. (2021). Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chinese Medical Journal, 134(11), 1289–1298. https://doi.org/10.1097/CM9.0000000000001573

Chicago

Hong-Xing Pan, Jian-Kai Liu, Bao-Ying Huang, Gui-Fan Li, Xian-Yun Chang, Ya-Fei Liu, Wen-Ling Wang, et al. 2021. “Immunogenicity and Safety of a Severe Acute Respiratory Syndrome Coronavirus 2 Inactivated Vaccine in Healthy Adults: Randomized, Double-Blind, and Placebo-Controlled Phase 1 and Phase 2 Clinical Trials.” Chinese Medical Journal 134 (11): 1289–98. doi:10.1097/CM9.0000000000001573.